A research collaboration to evaluate Opdivo® (nivolumab) and DS-8201 in HER2-expressing breast and bladder cancers.
Max Planck Innovation and Lead Discovery Center
An agreement between Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center.
A drug discovery and licensing agreement with Heptares Therapeutics that is focused on a single G protein-coupled receptor (GPCR) that plays a crucial role in relieving pain.
A strategic Partnership with Kite Pharma, a subsidary of Gilead Sciences, Inc. for the exclusive rights of development, manufacturing and commercialization in Japan of Kite’s cellular cancer therapy axicabtagene ciloleucel (KTE-C19) .
Inspirion Delivery Sciences
A collaboration to commercialize two abuse-deterrent opioid medications, MorphaBond™ ER and RoxyBond™, both of which feature a unique, patent-protected abuse-deterrent technology.
A strategic collaboration with AgonOx, Inc. to develop an undisclosed immuno-oncology target.
A cross-licensing and collaboration agreement to develop proprietary cancer immuno-oncology products.
Exclusive agreement to commercialize nine biosimilars in Japan, including biosimilars of adalimumab, bevacizumab and trastuzumab.
Exclusive license in Japan to develop and market Heartcel™, a immune-modulatory progenitor (iMP) cell therapeutic agent for ischemic heart failure.
A Co-commercialization agreement of Movantik™, a medication indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain in US.
Sanford-Burnham Medical Research Institute
A comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.
University of California, San Francisco
A drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases
Note: This is not a complete list of Daiichi Sankyo alliances